Navigation Links
Pharnext Supports the Fight Against Rare Diseases through Development of Pleotherapy-based Treatments

PARIS, Feb. 16, 2016 /PRNewswire/ -- Pharnext confirms its support and commitment to the fight against rare diseases on the occasion of the Worldwide Rare Disease Day taking place this year on February 29th. Pharnext is deeply involved in the development of new pleotherapy-based treatments using its network pharmacology approach for patients with rare neurological diseases as well as other neurological conditions with high unmet medical needs.

The 6,000 existing rare diseases affect approximately 580 million people worldwide including 60 million in Europe and North America. Many of these individuals suffer from the lack of safe and efficacious therapies for their serious conditions and from a lack of up-to-date information on their diseases.   

Pharnext's Pleodrugs are synergistic low-dose combinations of repositioned drugs with established safety profiles. These innovative therapies under development tackle simultaneously several disease targets potentially offering an excellent efficacy and safety profile. These are essential features for patients suffering from debilitating rare diseases.

Pharnext has two lead therapeutic candidates in development for severe orphan neurological diseases:

  • PXT-3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT 1A) in an international pivotal phase 3 trial - To date, no curative or symptom alleviating medications have been approved for CMT 1A patients and treatments for this rare neuromuscular disease consist only of supportive care
  • PXT-864 for the treatment of Amyotrophic Lateral Sclerosis (ALS) in a completed phase 1 trial - ALS is a very severe, life-threatening neurodegenerative disease; Currently approved treatments have very limited impact on life expectancy and do not improve quality of life for patients

Daniel Cohen, M.D., Ph.D., chairman, chief executive officer and co-founder of Pharnext, said, "We are absolutely committed to developing efficacious and safe new therapies for patients suffering from various rare diseases. From Pharnext's perspective, every patient counts and deserves the best therapeutic solution."

About Pharnext
Pharnext is an advanced clinical stage biopharmaceutical company developing novel therapeutics that simultaneously target multiple key disease pathways for severe orphan and common neurological disorders. The proprietary research and development platform of Pharnext, based on network pharmacology, is applicable to a broad spectrum of diseases and allows the rapid development of "pleodrugs", synergistic combinations of repositioned drugs with established safety profiles. The company's two lead pleodrugs are PXT-3003 for the treatment of orphan disease Charcot Marie Tooth type 1A (Phase 2 clinical trial completed) and PXT-864 for Alzheimer's disease (Phase 2 clinical trial ongoing) and other neurologic indications (including Parkinson's disease and amyotrophic lateral sclerosis).

For further information, visit


Pharnext contact
Daniel Cohen, M.D., Ph.D.
Chairman and Chief Executive Officer                                                                                 

Media Contacts
Tony Russo, Ph.D.
Matt Middleman, M.D.
Russo Partners
T: 212-845-4251
T: 212-845-4272

Florence Portejoie
Caroline Carmagnol
T : +33 1 44 54 36 64


SOURCE Pharnext
Copyright©2016 PR Newswire.
All rights reserved

Related biology technology :

1. Pharnext beginnt PLEO-CMT, eine internationale Phase-III-Zulassungsstudie bei Charcot-Marie-Tooth-Krankheit Typ 1A
2. Pharnext Initiates PLEO-CMT, an International Pivotal Phase 3 Trial, in Charcot-Marie-Tooth disease type 1A
3. Pharnexts PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting
4. Asymmetrex Supports UK RegMedNet with Sponsorship for Education on the Importance of Counting Adult Tissue Stem Cells in Regenerative Medicine Practice
5. AMIA Supports Efforts to Modernize Federal Research Protections
6. Biohaven Announces Phase 1 Pharmacokinetic Study Meets Study Objectives and Supports Advancing BHV-0223
7. Portages Biohaven announces Phase 1 pharmacokinetic study meets study objectives and supports advancing BHV-0223 and also appoints a CEO
8. New England Biolabs supports LabCentrals mission to help biotech startups develop and grow
9. uBiome Supports Oral Disease Prevention with Donations and Study
10. Immunexpress Supports World Sepsis Day 2015
11. Asterias Biotherapeutics Announces Publication of Preclinical Data that Supports the Safety and Use of AST-OPC1 as a Treatment for Spinal Cord Injury (SCI)
Post Your Comments:
(Date:6/2/2020)... ... June 01, 2020 , ... As part of its ongoing ... the world, enterprise security solutions provider bitsIO donated time to help two companies ... during self-quarantines and shelter-in-place orders, companies are increasingly concerned about the security of ...
(Date:5/28/2020)... ... May 28, 2020 , ... Genedata, ... release of Genedata Screener ® 17.0, the latest version of its enterprise ... in-vitro screening assay technologies. Genedata will host a webinar on June 10, 2020, ...
(Date:5/21/2020)... ... 21, 2020 , ... Threats to intellectual property, political pressure ... to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, ... the pandemic commercially weaker, dealing with delays in new product launches and with ...
(Date:5/21/2020)... CITY, Calif. (PRWEB) , ... May 20, 2020 ... ... announce the addition of Simon Prakash, who will serve as the company’s executive ... joins at a time when Exo is disrupting the medical imaging space, bringing ...
Breaking Biology Technology:
(Date:6/23/2020)... , ... June 23, 2020 , ... ... is pleased to announce the next event in a series of TOPIQ webinars, ... The TOPIQ series of webinars was developed in response to social distancing measures ...
(Date:6/13/2020)... ... June 11, 2020 , ... Bode Technology (Bode), ... forensic genealogy team. Bode’s Forensic Genealogy Service (FGS) continues to deliver ... analysis methods. The team has added experienced genealogists, each having over a decade ...
(Date:6/5/2020)... ... , ... Greffex, a pioneering vaccine and gene therapy company based in Houston, ... need for a global perspective to make an impact in a post pandemic world,” ... as an independent, director of the company. , “The Greffex board is excited to ...
Breaking Biology News(10 mins):